Apple’s new BCI HID protocol meets Synchron’s brain implant, unlocking mind-powered access for people with paralysis.
Brain-computer interface (BCI) pioneer Synchron announced it will be the first company to achieve native integration with Apple’s new BCI Human Interface Device (HID) profile, unveiled this week. This milestone allows people implanted with Synchron’s BCI to control iPhones, iPads, and Apple Vision Pro using only their thoughts—no touch, no voice, no physical movement required.
Apple’s introduction of the BCI HID protocol officially recognizes neural interfaces as a new category of input device across its ecosystem. For individuals with conditions like ALS, stroke, or spinal cord injuries, this technology opens up hands-free, voice-free control of digital devices, vastly improving accessibility.
Device Leverages Existing iPhone Features
Synchron’s BCI system will plug directly into Apple’s existing accessibility features, such as Switch Control, providing an intuitive and seamless user experience. This integration lays the groundwork for broader adoption of brain-driven input methods.
“This is a defining moment for how humans interact with technology,” said Dr. Tom Oxley, Synchron CEO and co-founder. “BCI is no longer just an accessibility tool—it’s a new layer of interface. Apple’s recognition of brain signals as native inputs alongside touch, voice, and typing changes the game for people with paralysis and beyond.”
Photo: Synchron
Historically, human interface devices—keyboards, mice, touchscreens—demanded physical movement. Voice commands expanded access, but still fall short for those with profound mobility challenges. Synchron’s Stentrode™ implant flips this model, translating neural activity into digital commands in real time, giving users control through thought alone.
Unlike traditional assistive tech that emulates physical inputs, a BCI HID enables two-way communication. This closed-loop design allows devices to share context—like screen layouts or interface elements—back to the BCI, fine-tuning performance and improving user experience.
“When we talk to clinical trial participants, their focus is always on communication and creativity,” said Kurt Haggstrom, Synchron’s Chief Commercial Officer. “For most people, that means using their Apple devices. Apple’s commitment to accessibility—and to listening to the needs of users—has been extraordinary. Working with their teams to help shape BCI HID has been an honor.”
A Real Breakthrough For ALS Patients
Blair Casey, CEO of Team Gleason, which advocates for people living with ALS, called the announcement a breakthrough: “For individuals who have lost nearly all voluntary movement, implantable BCIs offer life-changing potential. Apple isn’t just making accessible products; they’re setting new standards that expand what’s possible for people with disabilities.”
Synchron’s goal is bigger than iPhone control. The company envisions an open ecosystem where any BCI can connect seamlessly to any device. Collaboration across the industry will be key to making that vision a reality.
Synchron has been at the forefront of this field, becoming the first company to launch clinical trials of a permanently implantable BCI in 2019. Its minimally invasive approach, delivered via blood vessels rather than open brain surgery, positions it as the most scalable solution in clinical development.
With Apple’s native support for iOS, iPadOS, and visionOS, Synchron’s technology will soon reach more people, accelerating its path to commercialization. Controlled rollouts for clinical trial participants using BCI HID-compatible features are set to begin later this year.
For More Florida News, Click Here!
